*Purpose: Vaccine-induced thrombosis and thrombocytopenia (VITT) is a rare syndrome that has emerged since widespread vaccination against SARS-CoV-2. As a result of the high mortality, some patients have become deceased organ donors. Outcomes after kidney transplantation from donors with VITT are poorly described. Since the disease appears to be antibody-mediated, there is a theoretical risk of transmission from donor to recipient.

*Methods: We examined the UK experience of kidney transplantation from donors with VITT, using data from the UK Transplant Registry. Our outcomes were early graft function, post-operative complications, 3-month estimated glomerular filtration rate (eGFR), patient and graft survival, and disease transmission.

*Results: Thirty patients (including two aged <18 years) received a single kidney transplant from 16 donors with VITT between 1^st January and 30^th June 2021. After a median follow-up of 5 months, patient and graft survival were 97% and 90%, respectively. Median 3-month eGFR was 51 mL/min/1.73m². Two recipients had detectable anti-platelet factor 4 antibodies following transplantation, but no evidence of clinical disease. Major haemorrhagic or thrombotic complications occurred in three recipients, resulting in the loss of two grafts.

*Conclusions: The UK experience to date shows that favourable outcomes in kidney transplants from donors with VITT are possible. Ongoing vigilance for donor-related complications in these patients remains important.

« Back to 2022 American Transplant Congress